原发性胆汁性胆管炎患者血清核因子相关因子2、血红素加氧酶1的含量与熊去氧胆酸短期应答的相关性

doi:10.3877/cma.j.issn.1674-0785.2020.05.009

目的

观察核因子相关因子2（Nrf2）、血红素加氧酶1（HO-1）在原发性胆汁性胆管炎（PBC）患者治疗前后血清中的水平变化，并探讨二者与熊去氧胆酸（UDCA）短期疗效的相关性。

方法

纳入山西医科大学第一医院PBC患者及健康对照者各80例。收集PBC患者治疗前后的临床资料及血清样本，采用ELISA法检测样本中Nrf2及HO-1的含量，硫代巴比妥酸法、黄嘌呤氧化酶法分别检测丙二醛（MDA）及超氧化物歧化酶（SOD）的含量，并进一步分析UDCA治疗前后PBC患者血清中Nrf2、HO-1的水平变化及临床意义。

结果

治疗前PBC患者血清Nrf2、HO-1含量分别为（626.07±103.95）U/L、（16.62±5.06）U/L）显著高于健康对照者［分别为164.45±35.12）U/L、（11.74±2.0）U/L］，差异均有统计学意义（P均<0.001）；与治疗前比较，UDCA治疗后1个月PBC患者血清中Nrf2［（754.30±104.36）U/L］、HO-1［（22.60±5.51）U/L］含量显著增加（P均<0.001），肝功能各项指标也得到改善（P均<0.001）。患者治疗前血清中Nrf2水平（r=0.751，P=0.012）、HO-1水平（r=0.621，P=0.038）与治疗效果均呈正相关。以治疗前Nrf2=586.17 U/L作为阈值,预测的UDCA短期疗效的敏感度为84.6%，特异度为77.5%，曲线下面积为0.824（P<0.05）；以治疗前HO-1=14.92 U/L作为阈值，预测的UDCA短期疗效的敏感度为88.5%，特异度为75.0%，曲线下面积为0.861（P<0.05）。

结论

Nrf2、HO-1在PBC患者疾病过程中发挥重要作用，二者在血清中的基线水平及动态变化同UDCA疗效相关，可以提示PBC患者对UDCA短期治疗的应答情况。

关键词: 核因子相关因子2, 血红素加氧酶1, 原发性胆汁性胆管炎, 熊去氧胆酸, 氧化应激

Objective

To observe the changes of serum levels of nuclear factor-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) in patients with primary biliary cholangitis (PBC) before and after treatment, and to explore their correlation with short-term effects of ursodeoxycholic acid (UDCA).

Methods

A total of 80 patients with PBC and 80 healthy controls were enrolled at the First Hospital of Shanxi Medical University. The clinical data and serum samples of patients with PBC were collected before and after treatment. The contents of Nrf2 and HO-1 in the samples were detected by ELISA. The contents of malondialdehyde (MDA) and superoxide dismutase (SOD) were detected by the methods of tartaric acid and xanthine oxidase. The changes in serum Nrf2 and HO-1 levels in patients with PBC before and after UDCA treatment and their clinical significance were then analyzed.

Results

The contents of serum Nrf2 and HO-1 in PBC patients before treatment were [(626.07±103.95) U/L and (16.62±5.06 U/L), respectively], significantly higher than those of healthy controls [(164.45±35.12) U/L and (11.74±2.0) U/L, respectively; P<0.001]. Compared with the values before treatment, the contents of serum Nrf2 [(754.30±104.36) U/L] and HO-1 [(22.60±5.51)U/L] in PBC patients were increased significantly, and liver function indexes were also improved significantly after treatment (P<0.001). The increase of Nrf2 and HO-1 contents in the cured group and the marked group was particularly significant (P<0.001). The contents of serum Nrf2 (r=0.751, P=0.012) and HO-1 (r=0.621, P=0.038) before treatment were positively correlated with the treatment effect. Using pretreatment Nrf2=586.17 U/L as a threshold, the sensitivity for predicting short-term efficacy of UDCA was 84.6%, the specificity was 77.5%, and the area under the curve was 0.824 (P<0.05). Using pretreatment HO-1=14.92 U/L as a threshold, the sensitivity for predicting short-term efficacy of UDCA was 88.5%, the specificity was 75.0%, and the area under the curve was 0.861 (P<0.05).

Conclusion

Nrf2/HO-1 play an important role in the disease process of PBC patients. The baseline levels and dynamic changes of Nrf2/HO-1 in serum are related to the therapeutic effect of UDCA, which can predict the response of PBC patients to short-term treatment of UDCA.

Key words: Nuclear factor related factor 2, Heme oxygenase-1, Primary biliary cholangitis, Ursodeoxycholic acid, Oxidative stress

表1 80例原发性胆汁性胆管炎患者治疗前和熊去氧胆酸治疗后1个月各指标的比较

时间	生化指标
时间	ALT（U/L）	AST（U/L）	ALP（U/L）	GGT（U/L）	TBA（μmol/L）
治疗前	86.30±55.86	90.80±48.72	369.80±150.37	311.30±128.60	33.96±21.24
治疗后1个月	26.55±10.87	40.05±20.21	168.05±46.99	150.15±109.30	15.85±9.60
t值	3.067	3.743	4.012	3.421	4.236
P值	0.001	0.001	0.001	0.001	0.001
时间	生化指标		氧化应激指标
时间	TBIL（μmol/L）	DBIL（μmol/L）	MDA（nmol/ml）	SOD（U/ml）
治疗前	29.67±7.88	12.13±5.23	8.23±1.45	77.71±6.60
治疗后1个月	17.67±9.41	8.50±4.55	6.60±0.80	89.30±4.08
t值	3.011	1.056	3.301	3.907
P值	<0.05	>0.05	<0.05	<0.05

表1 80例原发性胆汁性胆管炎患者治疗前和熊去氧胆酸治疗后1个月各指标的比较

时间	生化指标
时间	ALT（U/L）	AST（U/L）	ALP（U/L）	GGT（U/L）	TBA（μmol/L）
治疗前	86.30±55.86	90.80±48.72	369.80±150.37	311.30±128.60	33.96±21.24
治疗后1个月	26.55±10.87	40.05±20.21	168.05±46.99	150.15±109.30	15.85±9.60
t值	3.067	3.743	4.012	3.421	4.236
P值	0.001	0.001	0.001	0.001	0.001
时间	生化指标		氧化应激指标
时间	TBIL（μmol/L）	DBIL（μmol/L）	MDA（nmol/ml）	SOD（U/ml）
治疗前	29.67±7.88	12.13±5.23	8.23±1.45	77.71±6.60
治疗后1个月	17.67±9.41	8.50±4.55	6.60±0.80	89.30±4.08
t值	3.011	1.056	3.301	3.907
P值	<0.05	>0.05	<0.05	<0.05

表2 PBC组治疗前、治疗后1个月与对照组Nrf2、HO-1的比较

组别		例数	Nrf2(U/L)	HO-1(U/L)
PBC组		?	?	?
?	治疗前	80	626.07±103.95^a	16.62±5.06^a
?	治疗后1个月	80	754.30±104.36^b	22.60±5.51^b
对照组		80	164.45±35.12	11.74±2.0
F值		?	35.061	14.152
P值		?	0.000	0.001

表2 PBC组治疗前、治疗后1个月与对照组Nrf2、HO-1的比较

组别		例数	Nrf2(U/L)	HO-1(U/L)
PBC组		?	?	?
?	治疗前	80	626.07±103.95^a	16.62±5.06^a
?	治疗后1个月	80	754.30±104.36^b	22.60±5.51^b
对照组		80	164.45±35.12	11.74±2.0
F值		?	35.061	14.152
P值		?	0.000	0.001

图1 熊去氧胆酸治疗前、治疗后1个月应答佳与应答不佳患者Nrf2（a）、HO-1（b）水平的变化

图2 血清中Nrf2、HO-1预测熊去氧胆酸短期疗效的ROC曲线

1	王璐，韩英. 《2018年美国肝病学会原发性胆汁性胆管炎实践指导》摘译 [J]. 临床肝胆病杂志, 2018, 34(11): 2300-2304.
2	葛均波，徐永健. 内科学 [M]. 8版. 北京: 人民卫生出版社, 2014: 413-415
3	Tonin F, Arends IWCE. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review [J]. Beilstein J Org Chem, 2018, 14(1): 470-483.
4	Loboda A, Damulewicz M, Pyza E, et al. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism [J]. Cell Mol Life Sc., 2016, 73(17): 3221-3247.
5	Cheng ML, Lu YF, Chen H，et al. Liver expression of Nrf2-related genes in different liver diseases [J]. Hepatobiliary Pancreat Dis Int, 2015, 14(5): 485-491.
6	Bell L N, Wulff J, Comerford M, et al. Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis [J]. Liver Int, 2015, 35(1): 263-274.
7	中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识(2015) [J]. 中华肝脏病杂志, 2015, 2(12): 924-933.
8	Marzorati S, Lleo A, Carbone M, et al. The epigenetics of PBC: The link between genetic susceptibility and environment [J]. Clin Res Hepatolo Gastroenterol, 2016: 40(6): 650-659.
9	Anthérieu S, Bachour-El Azzi P, Dumont J, et al. Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells [J]. Hepatology, 2013, 57(4): 1518-1529.
10	Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases [J]. World J Gastroenterol, 2014, 20(25): 8082-8091.
11	Webermzell D, Zaupa P, Petnehazy T, et al. The role of nuclear factor-kappa B in bacterial translocation in cholestatic rats [J]. Pediatr Surg Int, 2006, 22(1): 43-49.
12	Tanaka Y, Aleksunes LM, Cui YJ, et al. ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling [J]. Toxicol Sci, 2009, 108(2): 247-257.
13	Zhang L, Su H, Li Y, et al. Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice [J]. Toxicol Appl Pharmacol, 2018, 342: 69-78.
14	Elferink RP, Paulusma CC. MRP2 in cholestasis: putting down the anchor [J]. J Hepatol, 2015, 63(6): 1309-1310.
15	Ma X, Zhao Y, Zhu Y, et al. Paeonia lactiflora Pall protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway [J]. Drug Des Devel Ther, 2015, 9: 5061-5074.
16	Feng Y, Cui R, Li Z, et al. Methane Alleviates Acetaminophen-Induced Liver Injury by Inhibiting Inflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and Apoptosis through the Nrf2/HO-1/NQO1 Signaling Pathway [J]. Oxid Med Cell Longev, 2019, 2019: 7067619
17	Wu D, Wang Y, Zhang H, et al. Acacetin attenuates mice endotoxin- induced acute lung injury via augmentation of heme oxygenase-1 activity [J]. Inflammopharmacology, 2018, 26(2): 635-643.

[1]	鲁梦远, 赵学刚, 郝嘉文, 盖晨阳, 李聪颖, 张晶, 张庆富. 高压电烧伤大鼠肝脏氧化应激损伤及灯盏花素的干预作用[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(02): 113-118.
[2]	杨文飞, 郝嘉文, 鲁梦远, 赵学刚, 李聪颖, 盖晨阳, 张晶, 张庆富. 高压电烧伤对大鼠心肌氧化应激的影响及N-乙酰半胱氨酸的干预作用[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(02): 106-112.
[3]	李嘉兴, 孙乙文, 李文星. NLRP3炎性小体在急性胰腺炎中作用的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 300-304.
[4]	张璇, 高杨, 房雅君, 姚艳玲. 保护性机械通气在肺癌胸腔镜肺段切除术中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 563-567.
[5]	殷国青, 曾莉, 贺斌峰, 孙芬芬. Rab26负性调控Nrf2增强肺癌耐药细胞对奥希替尼的敏感性[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(03): 349-355.
[6]	王娟, 刘晔, 熊威, 蒋财磊, 贺燕, 叶青松. 间充质干细胞缓解阿尔茨海默病氧化应激的新思路[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 93-106.
[7]	裴捷, 毛本亮, 郝定盈, 苑伟, 颜勇, 吴帆, 王鹏珍, 王百林. 槲皮素调控肝缺血-再灌注损伤的研究进展及应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 244-249.
[8]	杜霞, 马梦青, 曹长春. 造影剂诱导的急性肾损伤的发病机制及干预靶点研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 279-282.
[9]	李佳曦, 刘子源, 李学民. 二甲双胍对年龄相关性白内障影响的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(04): 252-256.
[10]	王子琪, 李萍, 蔡标, 杨秀敏. 雌激素在糖尿病性视网膜病变中作用机制的研究进展[J/OL]. 中华眼科医学杂志(电子版), 2024, 14(03): 187-192.
[11]	李京, 牛博, 刘晓蓓, 魏新雪, 黄荣. circ-SESN2 沉默靶向调控miRNA-23a-5p/ULK1 在神经细胞氧化应激损伤中的作用机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 263-272.
[12]	冯铭, 孙洪涛. 动脉瘤性蛛网膜下腔出血的颅内压监测与管理[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 248-253.
[13]	张晟豪, 周杰, 姚鹏飞, 李长栋, 屈晓东, 南亚强, 曹丽. 雷公藤红素在创伤性脑损伤后继发性损伤中的作用及机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(03): 132-140.
[14]	王丽丽, 张春霞, 申磊, 吴立娜, 潘青, 冯雪. 吗替麦考酚酯联合雷公藤多苷及糖皮质激素治疗对IgA肾病患者肾功能、炎症因子和氧化应激的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(12): 1285-1290.
[15]	买买提·依斯热依力, 尹强, 尹海龙, 李治建, 董雨微, 王永康, 克力木·阿不都热依木, 阿吉艾克拜尔·艾萨. 罗乐胃蜜膏抑制酸刺激诱导食管上皮细胞炎症发生的机制研究[J/OL]. 中华胃食管反流病电子杂志, 2024, 11(03): 137-142.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between serum nuclear factor-related factor 2 and heme oxygenase-1 levels and short-term response to ursodeoxycholic acid in patients with primary biliary cholangitis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Correlation between serum nuclear factor-related factor 2 and heme oxygenase-1 levels and short-term response to ursodeoxycholic acid in patients with primary biliary cholangitis